DOTA Conjugated JM#21 derivative 7

Overview

DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney. DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

Application

Products | Products > Peptides | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Radionuclide-Drug Conjugates (RDCs) | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-P10444
• CAS No.: 3033865-40-3
• Molecular Formula: C66H114N22O16
• Molecular Weight: 1471.75
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source